在Ⅲ/Ⅳ期经典型霍奇金淋巴瘤（cHL）的一线治疗中，布伦妥单抗–顺铂、长春瑞滨、达卡巴嗪联合（BV+AVD）的应用日益增多。周围神经病变（PN）是临床试验中最常见且治疗限制性的副作用，但其在非试验环境中尚未进行研究，临床医生在管理PN时可能采用不同的策略。我们进行了一个多中心回顾性研究，以描述接受BV+AVD治疗的新诊断cHL患者的PN情况。来自10个美国机构的153名患者符合条件。其中34名患者（22%）至少有一个ECHELON-1的不合格标准，包括分期、活动状态和合并症。治疗期间，80%的患者报告有PN；39%的患者经历了G1级别的PN，31%的患者经历了G2级别的PN，10%的患者经历了G3级别的PN。总共44%的患者因PN导致BV剂量调整，其中23%停用，17%剂量减少，4%暂时停用。随访时间中位数为24个月，PN在最后的随访中得以解决的患者为36%，改善的患者为33%。晚期患者2年的无进展生存率（PFS）为82.7%（95% CI 0.76-0.90），总生存率（OS）为97.4%（95% CI 0.944-1.00）。因PN停用BV的患者无PFS劣势。在非试验环境中，BV+AVD与PN的发生率较高相关。在我们的队列中，包括那些不符合ECHELON-1试验关键标准的患者，BV停用率较之前报道的更高，但2年的结果仍然可比。版权所有©2023年美国血液学协会。

Brentuximab vedotin (BV) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) is increasingly used for frontline treatment of stage III/IV classical Hodgkin lymphoma (cHL). Peripheral neuropathy (PN) was the most common and treatment-limiting side effect seen in clinical trials but has not been studied in a non-trial setting, where clinicians may have different strategies for managing it.We conducted a multi-site retrospective study to characterize PN in patients who received BV+AVD for newly diagnosed cHL.153 patients from 10 US institutions were eligible. Thirty-four patients (22%) had at least 1 ineligibility criteria for ECHELON-1, including stage, performance status, and comorbidities. PN was reported by 80% of patients during treatment; 39% experienced grade (G) 1, 31% G2, and 10% G3. In total, BV was modified in 44% of patients due to PN leading to BV discontinuation in 23%, dose reduction in 17%, and temporary hold in 4%. With a median follow up of 24 months, PN resolution was documented in 36% and improvement in 33% at last follow up. 2-year progression-free survival (PFS) for the advanced stage patients was 82.7% (95% CI 0.76-0.90) and overall survival (OS) was 97.4% (95% CI 0.944-1.00). Patients who discontinued BV due to PN did not have inferior PFS.In the non-trial setting, BV+AVD was associated with a high incidence of PN. In our cohort, which includes patients who would not have been eligible for the pivotal ECHELON-1 trial, BV discontinuation rates were higher than previously reported, but 2-year outcomes remain comparable.Copyright © 2023 American Society of Hematology.